跳至主要内容
临床试验/EUCTR2014-005309-18-Outside-EU/EEA
EUCTR2014-005309-18-Outside-EU/EEA进行中(未招募)不适用

A Ph III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine Quinvaxem® (DTwP-Hib-HepB Vaccine) when Administered to Indian Infants at 6, 10, and 14 Weeks of Age

ovartis Vaccines and Diagnostics0 个研究点目标入组 175 人开始时间: 2014年12月10日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
175

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Male and female subjects = 42 days to = 64 days of age.
  • 2.Written informed consent obtained from either parents/ legal guardian after the nature of the study has been explained according to local regulatory requirements
  • 3.Subjects in good health as determined by the outcome of medical history, physical assessment and clinical judgment of the investigator
  • 4.Available for all scheduled study visits
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 175
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Subjects whose parents or legal guardians are unwilling or unable to give written informed consent to participate in the study.
  • 2.History of previous immunization with a vaccine containing any of the 5 antigen components of investigational vaccine.
  • 3.History of anaphylactic shock, urticaria or other allergic reactions after previous vaccination or known hypersensitivity to any vaccine component.
  • 4.Known or suspected impairment of immune function, known HIV positivity, receiving immunosuppressive therapy, or having received systemic immunosuppressive therapy within 1 month prior to study entry (note: inhaled and topical steroids are allowed)
  • 5.Administration of parenteral immunoglobulin preparation and/or blood products since birth
  • 6.Planned administration of a vaccine not foreseen by the study protocol
  • 7.Significant acute infection
  • 8.Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives
  • 9.Subject meeting with a nutritional status grades of I - IV according to the Indian Academy of Pediatrics (IAP) grading of nutritional status.
  • 10.Participation in another clinical trial

研究者

发起方
ovartis Vaccines and Diagnostics

相似试验

已完成
3 期
A clinical trial to Assess theImmunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine DTwP-Hib-HepB in Indian infants
CTRI/2011/11/002118ovartis Healthcare Pvt Ltd Vaccines Division175
进行中(未招募)
1 期
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments.Chronic Lymphocytic Leukemia
EUCTR2016-001097-15-BGAbbVie Deutschland GmbH & Co. KG200
已完成
3 期
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL)Cancer of the blood10024324Leukemia
NL-OMON55465AbbVie B.V.8
进行中(未招募)
1 期
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments.MedDRA version: 20.0Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic Lymphocytic Leukemia
EUCTR2016-001097-15-HUAbbVie Deutschland GmbH & Co. KG200
进行中(未招募)
1 期
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments.MedDRA version: 20.0Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic Lymphocytic Leukemia
EUCTR2016-001097-15-PLAbbVie Deutschland GmbH & Co. KG200